| Cardiac Fibrosis and Remodeling | Lifetime | 13 | US 8 | 99.57 |
| Inflammasome and immune disorders | Lifetime | 29 | US 11 | 99.48 |
| Pericarditis and Cardiac Tamponade | Lifetime | 11 | US 8 | 99.38 |
| Cardiac Ischemia and Reperfusion | Lifetime | 117 | US 66 | 98.91 |
| Signaling Pathways in Disease | Lifetime | 118 | US 70 | 98.38 |
| Kawasaki Disease and Coronary Complications | Lifetime | 57 | US 22 | 98.21 |
| Acute Myocardial Infarction Research | Lifetime | 337 | US 165 | 98.91 |
| Cardiovascular Function and Risk Factors | Lifetime | 706 | US 360 | 98.79 |
| COVID-19 Clinical Research Studies | Lifetime | 725 | US 170 | 97.45 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 443 | US 186 | 98.10 |
| Heart Failure Treatment and Management | Lifetime | 473 | US 230 | 98.28 |
| Long-Term Effects of COVID-19 | Lifetime | 563 | US 136 | 96.07 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 334 | US 147 | 97.67 |
| Viral Infections and Immunology Research | Lifetime | 544 | US 248 | 97.29 |
| Coronary Interventions and Diagnostics | Lifetime | 731 | US 300 | 97.99 |
| Pulmonary Hypertension Research and Treatments | Lifetime | 613 | US 298 | 97.21 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 108 | US 39 | 94.17 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 322 | US 165 | 94.01 |
| Myasthenia Gravis and Thymoma | Lifetime | 626 | US 205 | 93.47 |
| Inflammasome and immune disorders | 2021-2025 | 5 | US 3 | 99.58 |
| Viral Infections and Immunology Research | 2021-2025 | 12 | US 3 | 98.95 |
| Pericarditis and Cardiac Tamponade | 2021-2025 | 2 | US 1 | 99.12 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 16 | US 4 | 96.85 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 437 | US 135 | 97.04 |
| Heart Failure Treatment and Management | 2021-2025 | 314 | US 115 | 96.14 |
| Infective Endocarditis Diagnosis and Management | 2021-2025 | 358 | US 136 | 95.39 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 170 | US 35 | 91.98 |
| Acute Myocardial Infarction Research | 2021-2025 | 449 | US 107 | 94.67 |
| Myasthenia Gravis and Thymoma | 2021-2025 | 101 | US 22 | 93.25 |
| Takotsubo Cardiomyopathy and Associated Phenomena | 2021-2025 | 47 | US 5 | 90.25 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 142 | US 26 | 88.80 |
| Cardiovascular Effects of Exercise | 2021-2025 | 844 | US 224 | 83.29 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 379 | US 113 | 81.47 |
| Cardiovascular Syncope and Autonomic Disorders | 2021-2025 | 366 | US 112 | 80.10 |
| Kawasaki Disease and Coronary Complications | 2021-2025 | 487 | US 119 | 78.19 |
| Signaling Pathways in Disease | 2021-2025 | 556 | US 127 | 58.74 |
| Heart rate and cardiovascular health | 2021-2025 | 173 | US 37 | 47.41 |
